New Zealand Government Reverses Groundbreaking Anti-Smoking Legislation for Economic Reasons

Regulations by 2FIRSTS.ai
Nov.29.2023
New Zealand Government Reverses Groundbreaking Anti-Smoking Legislation for Economic Reasons
New Zealand's landmark smoking ban law, aimed at achieving a "smoke-free generation," has been repealed by the new government.

According to a report by Hipertextual, former New Zealand Prime Minister Jacinda Ardern announced a groundbreaking tobacco control law in 2021, with the aim of achieving a "smoke-free generation" and saving thousands of lives. The law received widespread support from health legislators around the world, with several countries announcing plans to follow suit. However, the new government in New Zealand repealed the law before it could be enacted, and openly admitted that the decision was driven by economic interests.

 

New Zealand's smoking ban bill aims to achieve its goals by gradually increasing the legal smoking age. Currently, in New Zealand and many other countries, the legal age for smoking is 18. The initial plan is to raise the age to 19 by 2026, followed by an annual increase of one year thereafter. Eventually, teenagers will no longer be permitted to smoke. Despite potentially appearing strict, this regulation is expected to save millions of lives and cost millions of dollars in healthcare expenses.

 

However, in the election, the newly elected government in New Zealand has promised to implement a historic tax reduction, which requires a complete overhaul. Given that the tobacco industry brings in a significant amount of revenue for the government, the newly elected right-wing coalition government wasted no time in making this decision.

 

Newly-appointed Minister of Finance, Nicola Willis, has announced the repeal of the smoking ban bill. This decision, driven by economic factors, did not originate from the Health Ministry. The tobacco industry contributes approximately $2 billion in tax revenue to the New Zealand government annually, making it an effective avenue for offsetting tax deductions.

 

A recent study suggests that Ardern's smoking ban bill could save $1.3 billion in healthcare costs over the next 20 years. However, this does not offset the profits from tobacco sales, thus making it an insufficiently compelling reason for the new government.

 

Furthermore, the World Health Organization (WHO) stated in its tobacco report that approximately 8 million people die each year globally due to smoking-related causes. Out of this number, 7 million people die directly from smoking, while the remaining 1 million are second-hand smoke inhalers. These individuals do not willingly smoke, yet they tragically lose their lives due to exposure to cigarette smoke.

 

Achieving a smoke-free generation is just one of the many proposed measures by the World Health Organization to prevent health issues caused by tobacco. Other measures include conducting health promotion campaigns to assist people in quitting smoking, issuing graphic health warnings, increasing taxes on tobacco companies, and regulating nicotine-containing products such as e-cigarettes.

 

At the beginning of this year, the Director-General of the organization, Tedros Adhanom Ghebreyesus, stated that only four countries in the world have implemented a comprehensive set of measures following most of the organization's recommendations. These countries include Brazil, Mauritius, Turkey, and the Netherlands. Among the member states of the European Union, only the Netherlands has achieved this feat. However, data shows that approximately 18.4% of the population aged 15 and above reported being daily smokers in 2019. The highest smoking rate was recorded in Bulgaria at 28.7%, while Sweden had the lowest at 6.4%.

 

Fortunately, several countries, such as Portugal, have started implementing the smoking ban law repealed by New Zealand and have also set goals to achieve a smoke-free generation.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23
Athletes Back Skoka's $21.5 Million Nicotine Pouch Venture: Can Its Consumer Health Founder Make an FDA-Focused Strategy Pay Off?
Athletes Back Skoka's $21.5 Million Nicotine Pouch Venture: Can Its Consumer Health Founder Make an FDA-Focused Strategy Pay Off?
U.S. nicotine pouch startup Skoka Inc. has raised $21.5 million and committed $15 million to an FDA regulatory and scientific research program. Founder Dan Aziz previously built dietary supplement brand Premama, which was acquired by Dr. Reddy's Laboratories in 2023. Skoka is combining proprietary formulations, ingredient transparency and equity investment from professional athletes. The company submitted a bundled PMTA covering 55 products on October 1, 2026. Aziz said Skoka declined an opportunity to enter retail in 2025, prioritizing product research and regulatory submissions instead. It now targets a U.S. retail launch in 2027, subject to FDA requirements. Its products have not received marketing authorization.
Business
Nov.04
UK-Listed Consumer Goods Group Supreme Sees Vape Duty as Potential Consolidation Opportunity, Holds FY27 Outlook
UK-Listed Consumer Goods Group Supreme Sees Vape Duty as Potential Consolidation Opportunity, Holds FY27 Outlook
UK-listed consumer goods group Supreme plc says it continues to expect FY27 trading to meet market expectations as the Vaping Products Duty takes effect on October 1, while maintaining a comparatively positive view of the new tax and compliance regime. Supreme has said the framework could increase compliance complexity for smaller operators and contribute to market consolidation, while its manufacturing, compliance and distribution scale may allow it to gain share. Its 88Vape brand will retain its value positioning.
Sep.18
How Many Nicotine Pouch Factories Does Europe Need? 2Firsts Interviews AIRSCREAM on the OEM Market
How Many Nicotine Pouch Factories Does Europe Need? 2Firsts Interviews AIRSCREAM on the OEM Market
At InterTabac 2026, nicotine pouch growth was visible not only in brands but across equipment, raw materials and OEM manufacturing. 2Firsts interviewed AIRSCREAM commercial head Steve Moore on how many pouch factories Europe may ultimately need and where manufacturers can differentiate, from formulation and flavour to pouch materials, production consistency and customer service. The category continues to expand, but questions remain over future capacity, consolidation and the long-term structure of the supply chain.
Sep.18
Arizona Turns to a 50% Retail Vape Tax as Tobacco Tax Revenue Falls 47% From 2008
Arizona Turns to a 50% Retail Vape Tax as Tobacco Tax Revenue Falls 47% From 2008
Arizona's First Things First is pushing for an excise tax equal to 50% of the retail price of vaping products, estimating that the measure could generate about $100 million annually. The agency says its tobacco-tax revenue has fallen 47% from 2008 levels. Arizona has attempted to broaden its nicotine tax base in each of the past two years: a 2025 bill proposed a 50% wholesale-price tax, while a 2026 measure shifted to a 50% retail-price tax covering alternative nicotine products and vapor products. Separately, the state enacted HB 4001 this year to establish a new licensing and sales framework for alternative nicotine products.
Sep.21
FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
The U.S. Food and Drug Administration has revised the rules under Import Alert 98-07 to incorporate its May 2026 enforcement-priority policy for certain electronic nicotine delivery systems marketed without premarket authorization. The alert continues to allow detention without physical examination, or DWPE, for ENDS lacking required marketing authorization, while directing field divisions to apply the May risk-based framework. When necessary, detention or refusal decisions must also undergo review by the FDA's Center for Tobacco Products. Products including PACHA and Vuse Pro have already emerged as industry examples of the May policy, although enforcement discretion does not constitute FDA marketing authorization.
News
Sep.28 by 2Firsts Perspectives